Document is current
Any future updates will be listed below
-
Authors
Goto, Taichi https://orcid.org/0000-0001-7140-8175
Kreskow, Joy D.
Ross, Alexander L. R. https://orcid.org/0000-0001-6107-1927
Blumhorst, Catherine L. https://orcid.org/0009-0003-7746-6351
Zhao, Justin J. https://orcid.org/0009-0002-8626-2089
Mannes, Andrew J. https://orcid.org/0000-0001-5834-5667
Bačkonja, Miroslav
Zarate Jr, Carlos A. https://orcid.org/0000-0003-4442-7412
Saligan, Leorey N. https://orcid.org/0000-0001-9481-7836
- License Information
-
More Information
Article History
Received: 5 March 2025
Revised: 31 July 2025
Accepted: 20 November 2025
First Online: 22 January 2026
Declarations
:
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co–inventor on a patent for the use of (2R,6R)–hydroxynorketamine, (S–dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S–ketamine in the treatment of depression and neuropathic pain; and as a co–inventor on a patent application for the use of (2R,6R)–hydroxynorketamine and (2S,6S)–hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post–traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
